Filing Details

Accession Number:
0001140361-22-038695
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-10-27 18:00:42
Reporting Period:
2022-10-25
Accepted Time:
2022-10-27 18:00:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1635088 Roivant Sciences Ltd. ROIV Pharmaceutical Preparations (2834) 981173944
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1750094 Matthew Gline C/O Roivant Sciences Ltd.
7Th Floor, 50 Broadway
London X0 SW1H 0DB
Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2022-10-25 19,276 $4.40 1,164,009 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person.
  2. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.